MYOS Co. (NASDAQ:MYOS) Short Interest Update

MYOS Co. (NASDAQ:MYOS) was the target of a large drop in short interest in the month of November. As of November 29th, there was short interest totalling 63,900 shares, a drop of 12.2% from the November 14th total of 72,800 shares. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is presently 7.8 days. Currently, 1.3% of the company’s shares are sold short.

NASDAQ:MYOS traded down $0.04 during mid-day trading on Friday, hitting $1.38. 18,147 shares of the company’s stock were exchanged, compared to its average volume of 6,453. The company has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $1.49. The company has a current ratio of 2.06, a quick ratio of 0.51 and a debt-to-equity ratio of 0.07. MYOS has a fifty-two week low of $1.15 and a fifty-two week high of $2.02. The firm has a market capitalization of $13.40 million, a P/E ratio of -3.07 and a beta of 0.92.

Separately, ValuEngine upgraded shares of MYOS from a “hold” rating to a “buy” rating in a research report on Wednesday.

An institutional investor recently raised its position in MYOS stock. Community Capital Management Inc. increased its holdings in shares of MYOS Co. (NASDAQ:MYOS) by 295.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 142,452 shares of the company’s stock after buying an additional 106,392 shares during the period. Community Capital Management Inc. owned about 1.55% of MYOS worth $217,000 at the end of the most recent quarter. 5.93% of the stock is owned by institutional investors.

MYOS Company Profile

MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

See Also: Discount Rate

Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with's FREE daily email newsletter.